Scholarlink

Background <p>Diabetes and pancreatic cancer (PC) may concurrently affect the same individual. In such patients, receiving both anti-diabetic drugs and anti-tumor therapy is indispensable to control disease progression. In recent years, immunotherapy has brought significant advances in cancer treatment. However, as one of the most common classes of antidiabetic medications, the role of sulfonylureas (SUs) in PC remains largely unknown, and their clinical application in immunotherapy is still limited.</p> Methods <p>A murine syngeneic Pan02 pancreatic cancer model was established to assess the impact of glimepiride and gliclazide combined with programmed cell death protein 1 antibody(PD1ab), respectively. Immunohistochemistry was conducted to examine the number of infiltrated CD8<sup>+</sup> T cells. In vitro and in vivo assays, including the CCK8 and Transwell migration assays, were utilized to study the direct effects of glimepiride and gliclazide on human pancreatic cancer cells Panc-1. To explore the preliminary mechanism, bioinformatics analyses were performed, including bioinformatics analysis, Western Blot (WB), and lentiviral transduction and transfection.</p> Results <p>Treatment with the SUs glimepiride and gliclazide treatment alone significantly inhibited the proliferation of subcutaneously grafted Pan02 cells in C57BL6/c mice. Furthermore, both agents showed a potential therapeutic effect on PD1ab. IHC examination showed that gliclazide induced higher CD8<sup>+</sup> T cell infiltration. In vitro experiments utilizing human pancreatic cancer cells Panc-1 demonstrated that glimepiride and gliclazide significantly suppressed tumor proliferation and migration. The in vivo results supported the above conclusion. Moreover, the bioinformatics results indicated that Capn2 may be the targets of SUs and was negatively associated with CD8<sup>+</sup> T cell infiltration and were closely associated with overall survival or disease-free survival in PC patients. <i>In-vitro</i> and <i>in-vivo</i> experiments verified that Capn2 may mediate the therapeutic effects of SUs against PC.</p> Conclusion <p>The study revealed that SUs may prevent tumor growth by modulating Capn2 and potentiating the therapeutic effect of PD1ab, which may hold potential for PC therapy. This study provides novel insights for the medical application of SUs and should be confirmed by clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sulfonylureas Glimepiride and Gliclazide Prevent Pancreatic Cancer Progression by Modulating Capn2 and Strengthening Tumor Immunotherapy

  • 期刊论文

  • 发表日期：

    2025年2月5日

查看全文
  • Zilong Chen,
  • Yuhuai Wang,
  • Defu Zhao,
  • Yunan Lin,
  • Ling He

摘要

Background

Diabetes and pancreatic cancer (PC) may concurrently affect the same individual. In such patients, receiving both anti-diabetic drugs and anti-tumor therapy is indispensable to control disease progression. In recent years, immunotherapy has brought significant advances in cancer treatment. However, as one of the most common classes of antidiabetic medications, the role of sulfonylureas (SUs) in PC remains largely unknown, and their clinical application in immunotherapy is still limited.

Methods

A murine syngeneic Pan02 pancreatic cancer model was established to assess the impact of glimepiride and gliclazide combined with programmed cell death protein 1 antibody(PD1ab), respectively. Immunohistochemistry was conducted to examine the number of infiltrated CD8+ T cells. In vitro and in vivo assays, including the CCK8 and Transwell migration assays, were utilized to study the direct effects of glimepiride and gliclazide on human pancreatic cancer cells Panc-1. To explore the preliminary mechanism, bioinformatics analyses were performed, including bioinformatics analysis, Western Blot (WB), and lentiviral transduction and transfection.

Results

Treatment with the SUs glimepiride and gliclazide treatment alone significantly inhibited the proliferation of subcutaneously grafted Pan02 cells in C57BL6/c mice. Furthermore, both agents showed a potential therapeutic effect on PD1ab. IHC examination showed that gliclazide induced higher CD8+ T cell infiltration. In vitro experiments utilizing human pancreatic cancer cells Panc-1 demonstrated that glimepiride and gliclazide significantly suppressed tumor proliferation and migration. The in vivo results supported the above conclusion. Moreover, the bioinformatics results indicated that Capn2 may be the targets of SUs and was negatively associated with CD8+ T cell infiltration and were closely associated with overall survival or disease-free survival in PC patients. In-vitro and in-vivo experiments verified that Capn2 may mediate the therapeutic effects of SUs against PC.

Conclusion

The study revealed that SUs may prevent tumor growth by modulating Capn2 and potentiating the therapeutic effect of PD1ab, which may hold potential for PC therapy. This study provides novel insights for the medical application of SUs and should be confirmed by clinical trials.